Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemborexant for prevention of postoperative delirium after gastrointestinal cancer surgery
jRCTs041240116Phase 2Recruiting
- Sponsor
- Hamamatsu University School of Medicine
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lemborexant in postoperative delirium (POD) (2 arms), sponsored by Hamamatsu University School of Medicine. Primary endpoint: Occurrence of delirium in first postoperative week. Started Nov 2024; status: recruiting.
02
Drugs
lemborexant
03
Conditions
postoperative delirium (POD)
Beyond the preview
Go deeper on jRCTs041240116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240116.